MedPath

Bare -Metal Stents and Drug -Eluting Stents in the Treatment of Patients With Vertebral Artery Ostium Stenosis

Completed
Conditions
Ischemic Stroke
Interventions
Procedure: DES group
Procedure: BMS group
Registration Number
NCT02197559
Lead Sponsor
Xuanwu Hospital, Beijing
Brief Summary

The study hypothesizes that Drug -eluting stents are more effective in preventing restenosis than Bare-metal stents after Vertebral Artery Ostium stenting

Detailed Description

The vertebral artery ostium stenosis was one of the higher risk of the ischemia stroke in China. In the mean time ,more and more people accept revascularization. There are no prospective studies for comparison of prevention of restenosis after Drug -eluting stents and Bare-metal stents until now.

The main aim of this study is to observe the following details:

1. Late loss in lumen diameter in follow-up ≥50%

2. Death, non -fatal stroke 30 days after stent implantation associated with antiplatelet drugs

3. Death, non -fatal stroke 12 months after stent implantation associated with antiplatelet drugs

Secondary endpoint:

brain, gastrointestinal and urinary system bleeding in 12 months follow-up

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
168
Inclusion Criteria
  • symptomatic posterior circulation ischemia including monor stroke (mRS ≤2) or TIA result from the stenosis in the vertebral artery ostium.

70% to 99% stenosis of vertebral artery ostium.

Exclusion Criteria
  • etiology of stenotic lesions not atherosclerosis patients had undergone previos interventions on the vertebral artery ostium ipsilateral severe stenotic lesions in subclavian artery involved as well as vertebral artery ostium

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
BMS group, DES groupDES groupAll the participants in this group will be performed with bare-metal stents or drug -eluting stents
BMS group, DES groupBMS groupAll the participants in this group will be performed with bare-metal stents or drug -eluting stents
Primary Outcome Measures
NameTimeMethod
Late loss in lumen diameter in follow-up ≥50%1 year

Late loss in lumen diameter in follow-up ≥50%

Death, non -fatal stroke 12 months after stent implantation associated with antiplatelet drugs12 months

Death, non -fatal stroke 12 months after stent implantation associated with antiplatelet drugs

Death, non -fatal stroke 30 days after stent implantation associated with antiplatelet drugs30 days

Death, non -fatal stroke 30 days after stent implantation associated with antiplatelet drugs

Secondary Outcome Measures
NameTimeMethod
brain, gastrointestinal and urinary system bleeding in 12 months follow-up12 months

brain, gastrointestinal and urinary system bleeding in 12 months follow-up

Trial Locations

Locations (1)

Department of neurosurgery, Xuanwu hospital

🇨🇳

Beijing, China

© Copyright 2025. All Rights Reserved by MedPath